ALC250117P75000
- 0.10
- 0.000.00%
Alcon Newsroom
UBS Maintains Alcon(ALC.US) With Buy Rating, Raises Target Price to $104.6
Berenberg Bank Maintains Alcon(ALC.US) With Buy Rating, Cuts Target Price to $101.94
Berenberg Bank Reaffirms Their Buy Rating on Alcon (ALC)
Redburn Atlantic Upgrades Alcon(ALC.US) to Buy Rating, Raises Target Price to $102.3
Alcon Upgraded to Buy From Neutral at Redburn Atlantic
Stifel Maintains Alcon(ALC.US) With Buy Rating, Announces Target Price $100
Stifel Maintains Alcon(ALC.US) With Buy Rating
Stifel Nicolaus Remains a Buy on Alcon (ALC)
UBS Maintains Alcon(ALC.US) With Buy Rating, Cuts Target Price to $105.57
Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV), Alcon (ALC) and Humana (HUM)
Needham Maintains Alcon(ALC.US) With Buy Rating, Raises Target Price to $108
Alcon Is Maintained at Buy by Needham
Alcon Analyst Ratings
UBS Maintains Alcon(ALC.US) With Buy Rating, Cuts Target Price to $107.55
Analysts Are Bullish on Top Healthcare Stocks: Haemonetics (HAE), Alcon (ALC)
UBS Maintains Alcon(ALC.US) With Buy Rating, Raises Target Price to $107.25
Deutsche Bank Maintains Alcon(ALC.US) With Buy Rating, Cuts Target Price to $92.9
J.P. Morgan Maintains Alcon(ALC.US) With Buy Rating, Cuts Target Price to $89.5
Analysts Conflicted on These Healthcare Names: Alcon (ALC), Innate Pharma SA (OtherIPHYF) and ScPharmaceuticals (SCPH)
BofA Securities Maintains Alcon(ALC.US) With Hold Rating, Cuts Target Price to $93.63